Ventrus Biosciences Receives Date for Type B Pre-NDA Meeting With FDA for DOLIZEM (Diltiazem Hydrochloride Cream) in Anal Fissures

[GlobeNewswire] – NEW YORK — Ventrus Biosciences, Inc. , a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that, in response to a request from the company, the … more

View todays social media effects on VTUS

View the latest stocks trending across Twitter. Click to view dashboard

See who Ventrus is hiring next, click here to view